aTyr Pharma, Inc. (NASDAQ:LIFE) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $5.75 and last traded at $5.60, with a volume of 418,980 shares changing hands. The stock had previously closed at $4.75.

A number of research firms have commented on LIFE. Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Wednesday, September 13th. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the company a “hold” rating in a research report on Tuesday, August 15th. Piper Jaffray Companies began coverage on aTyr Pharma in a research report on Thursday, September 7th. They set an “overweight” rating and a $7.00 price target for the company. Finally, ValuEngine lowered aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.62.

The stock has a 50-day moving average of $4.19 and a 200 day moving average of $4.19. The stock’s market capitalization is $135.88 million.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.06. On average, equities research analysts expect that aTyr Pharma, Inc. will post ($2.18) earnings per share for the current fiscal year.

In other news, Director Paul Schimmel purchased 94,336 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the completion of the acquisition, the director now owns 40,440 shares of the company’s stock, valued at $107,166. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Mendlein purchased 37,736 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by insiders.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its holdings in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,800 shares of the biotechnology company’s stock after purchasing an additional 700 shares during the period. Renaissance Technologies LLC owned 0.16% of aTyr Pharma worth $136,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/atyr-pharma-inc-life-reaches-new-12-month-high-at-5-75/1611473.html.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.